Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence-Reference-Cited by-同舟云学术

Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence

Published:2019-08-01 Issue:22 Volume:37 Page:1980-1981
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Braal C. Louwrens¹,Beijnen Jos H.¹,Koolen Stijn L.W.¹,Oomen-de Hoop Esther¹,Steeghs Neeltje¹,Jager Agnes¹,Huitema Alwin D.R.¹,Mathijssen Ron H.J.¹

Affiliation:

1. C. Louwrens Braal, PharmD, Erasmus University Medical Center, Rotterdam, the Netherlands; Jos H. Beijnen, PhD, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands, and Utrecht University, Utrecht, the Netherlands; Stijn L.W. Koolen, PhD, PharmD and Esther Oomen-de Hoop, PhD, Erasmus University Medical Center, Rotterdam, the Netherlands; Neeltje Steeghs, MD, PhD, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands; Agnes Jager, MD, PhD,...

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.19.00418

Reference10 articles.

1. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

3. Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

4. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

5. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?;Drugs;2024-03-14

2. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer;Breast Cancer Research and Treatment;2023-04-17

3. The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer;ESMO Open;2023-02

4. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial;Breast Cancer Research and Treatment;2022-07-16

5. (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study;Journal of Personalized Medicine;2022-03-22